MTPAP

Across TCGA pan-cancer cohorts, MTPAP mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated MTPAP data layer compared with 25 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher MTPAP mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated MTPAP expression acts as an unfavorable survival marker, although some lineages such as CCRCC show a favorable association.

PDAC, CCRCC, and HNSC are the cancer types where MTPAP mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Quartile	III,IV	0.289	0.951	.002	19	view →
CCRCC	OS	Median	III,IV	0.791	0.582	.010	12	view →
HNSC	DFS	Quartile	III,IV	0.647	0.963	.009	7	view →
LUAD	DFS	Median	II,III,IV	0.229	0.774	.004	7	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

MTPAP–PDAC (DFS)

Open the PDAC breakdown →